Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
作者： Mizuki Nishino , Suzanne E. Dahlberg , Linnea E. Fulton , Subba R. Digumarthy , Hiroto Hatabu
DOI: 10.1016/J.ACRA.2015.11.005
关键词:
摘要: Rationale and Objectives The aims of this study were to investigate the association between 8-week tumor volume decrease survival in an independent cohort epidermal growth factor receptor ( EGFR )-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, assess rate their volumetric after nadir. Materials Methods In NSCLC harboring sensitizing mutations computed tomography (CT) volumes dominant lesions analyzed for (1) survival, (2) Results 44 follow-up CT, (%) was significantly associated longer overall when fitted as a continuous variable Cox model P = 0.01). logarithm (log e V), obtained using linear mixed-effects adjusting time since baseline, 0.096/month (SE: 0.013/month; 95% confidence interval [CI]: 0.071–0.12/month), which similar 0.12/month 0.015/month; 95%CI: 0.090–0.15/month) observed previous report. Conclusions validated marker -mutant gefitinib. nadir that cohort, indicating reproducibility observation among different patient cohorts.
sci-hub.se 参考文章(46)
Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Nikhil H. Ramaiya, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson, Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy Cancer. ,vol. 119, pp. 3761- 3768 ,(2013) , 10.1002/CNCR.28290
Mizuki Nishino, Mengye Guo, David M. Jackman, Pamela J. DiPiro, Jeffrey T. Yap, Tak K. Ho, Hiroto Hatabu, Pasi A. Jänne, Annick D. Van den Abbeele, Bruce E. Johnson, CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Academic Radiology. ,vol. 18, pp. 54- 62 ,(2011) , 10.1016/J.ACRA.2010.08.021
Graziella Pratesi, Roberto Foroni, Monica Tortoreto, Antonella Ingrosso, Romano Demicheli, Carla Soranzo, An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Research. ,vol. 49, pp. 6543- 6546 ,(1989)
Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, David M. Jackman, Nikhil H. Ramaiya, Hiroto Hatabu, Michael S. Rabin, Pasi A. Jnne, Bruce E. Johnson, Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors Lung Cancer. ,vol. 79, pp. 283- 288 ,(2013) , 10.1016/J.LUNGCAN.2012.11.007
Toshihiko Sato, Atsushi Watanabe, Haruhiko Kondo, Masato Kanzaki, Kenichi Okubo, Kohei Yokoi, Kazuya Matsumoto, Takashi Marutsuka, Hirohiko Shinohara, Satoshi Teramukai, Kazuma Kishi, Masahito Ebina, Yukihiko Sugiyama, Okumora Meinoshin, Hiroshi Date, Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases The Journal of Thoracic and Cardiovascular Surgery. ,vol. 149, pp. 64- 70.e2 ,(2015) , 10.1016/J.JTCVS.2014.08.086
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
Motoyasu Kato, Takehito Shukuya, Fumiyuki Takahashi, Keita Mori, Kentaro Suina, Tetsuhiko Asao, Ryota Kanemaru, Yuichiro Honma, Keiko Muraki, Koji Sugano, Rina Shibayama, Ryo Koyama, Naoko Shimada, Kazuhisa Takahashi, Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease BMC Cancer. ,vol. 14, pp. 508- 508 ,(2014) , 10.1186/1471-2407-14-508
Kate McKeage, Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer Drugs. ,vol. 75, pp. 75- 82 ,(2015) , 10.1007/S40265-014-0329-Y
Carlos Gomez-Roca, Serge Koscielny, Vincent Ribrag, Clarisse Dromain, Inès Marzouk, François Bidault, Ratislav Bahleda, Charles Ferté, Christophe Massard, Jean-Charles Soria, Tumour growth rates and RECIST criteria in early drug development European Journal of Cancer. ,vol. 47, pp. 2512- 2516 ,(2011) , 10.1016/J.EJCA.2011.06.012
Binsheng Zhao, Lawrence H. Schwartz, Chaya S. Moskowitz, Michelle S. Ginsberg, Naiyer A. Rizvi, Mark G. Kris, Lung cancer: computerized quantification of tumor response--initial results. Radiology. ,vol. 241, pp. 892- 898 ,(2006) , 10.1148/RADIOL.2413051887